Evidence Regarding Pharmacogenetics in Pain Management and Cancer

por Smith, D Max, Figg, William D
Publicado 2023

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

por Sissung, Tristan M., Figg, William D.
Publicado 2022

Lutetium-177-PSMA-617: A Vision of the Future

por Chandran, Elias, Figg, William D., Madan, Ravi
Publicado 2022

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

por Scripture, Charity D, Figg, William D, Sparreboom, Alex
Publicado 2005

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures

por Huang, Xuan, Chau, Cindy H, Figg, William D
Publicado 2012

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance

por Huang, Phoebe A., Price, Douglas K., Figg, William D.
Publicado 2018

Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics

por Hall, O. Morgan, Peer, Cody J., Figg, William D.
Publicado 2018

Are sex discordant outcomes in COVID-19 related to sex hormones?

por Strope, Jonathan D., Chau, Cindy H., Figg, William D.
Publicado 2020

Single whole genome sequencing analysis blazes the trail for precision medicine

por Napoli, Giulia C., Chau, Cindy H., Figg, William D.
Publicado 2022

Functional Drug Screening in the Era of Precision Medicine

por Napoli, Giulia C., Figg, William D., Chau, Cindy H.
Publicado 2022

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

por Gardner, Erin R, Smith, Nicola F, Figg, William D, Sparreboom, Alex
Publicado 2009

The Role of MRI in Prostate Cancer Active Surveillance

por Johnson, Linda M., Choyke, Peter L., Figg, William D., Turkbey, Baris
Publicado 2014

TMPRSS2: Potential Biomarker for COVID‐19 Outcomes

por Strope, Jonathan D., PharmD, Cindy H. Chau, Figg, William D.
Publicado 2020

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

por Handy, Whitney F., Schmidt, Keith T., Price, Douglas K., Figg, William D.
Publicado 2020

Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management

por Doan, David K., Schmidt, Keith T., Chau, Cindy H., Figg, William D.
Publicado 2021

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

por Lee, Kristi Y., Chau, Cindy H., Price, Douglas K., Figg, William D.
Publicado 2022

Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression

por Pressler, Heather, Sissung, Tristan M., Venzon, David, Price, Douglas K., Figg, William D.
Publicado 2011

Precision medicine applications in prostate cancer

por McCrea, Edel M., Lee, Daniel K., Sissung, Tristan M., Figg, William D.
Publicado 2018

Targeting the metastatic niche: Single-cell lineage tracing in prime time

por Sommer, Elijah R., Napoli, Giulia C., Chau, Cindy H., Price, Douglas K., Figg, William D.
Publicado 2023

Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model

por Beedie, Shaunna L., Mahony, Chris, Walker, Heather M., Chau, Cindy H., Figg, William D., Vargesson, Neil
Publicado 2016